GlassScriptPhysician profile
Geetha Kandimala
NPI 1922200435
$36,808.93
in general payments reported to CMS, 2019-2025
52 companies · $4,646 in 2025
The $4,646 reported for 2025 was more than what 84% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,582 · 2020: $1,411 · 2021: $8,209 · 2022: $16K · 2023: $1,601 · 2024: $1,202 · 2025: $4,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,907 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $375 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,906.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $375.00 |
| Education | $166.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,427.81 | 2021-2025 | |
| Livanova USA, INC. | $1,846.14 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic USA, INC. | $1,145.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $1,094.38 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ucb, INC. | $914.47 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Novartis Pharmaceuticals Corporation | $861.92 | 2019-2025 | |
| Sk Life Science, INC. | $854.16 | 2020-2025 | |
| Lundbeck LLC | $683.87 | 2019-2025 | Vyepti, Rexulti |
| Biogen, INC. | $669.25 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Neurocrine Biosciences, INC. | $624.35 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $622.39 | 2019-2025 | |
| Amgen INC. | $592.89 | 2019-2025 | Uplizna |
| Argenx US, INC. | $460.93 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Supernus Pharmaceuticals, INC. | $450.10 | 2019-2022 | |
| Lilly USA, LLC | $408.92 | 2019-2025 | Kisunla, Reyvow, Emgality |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geetha Kandimala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.